Table 5.

Adjusted odds ratios and 95% confidence intervals from multiple logistic regression in cerebral infarction^*

Variables	Adjusted OR	95% CI	p-value
(Intercept)	3.649383e+06	0.00 – 4.410196e+298	0.9989
Gender†	5.55	0.03 – 5.986921e+04	0.5902
AgeOp††	0.98	0.82 – 1.13	0.7643
SubGroup 1†††	7.379513e+10	0 – Inf	0.9989
SubGroup 2†††	230.78	0 – Inf	0.9999
DAPTG 6††††	19.82	0.50 – 5050.15	0.1653
DAPTG 9††††	0	0.00 – 1.589189e+189	0.9988
DAPTG 12††††	0	0 – Inf	0.9990
DAPTG 13††††	273	3.35 – 2.300476e+05	0.0353
Diabetes	2.55	0.04 – 586.27	0.6789
Hypertension	3.082790e+07	0.00 – 5.446095e+113	0.9974
Cardiovascular disease	4.05	0.01 – 646.67	0.5401
Aspirin	0.03	0.00 – 2.16	0.1346
Other antiplatelets	0.03	0.00 – 0.34	0.0173
Anticoagulants	0	NA – Inf	0.9995
Nonsteroidal anti-inflammatory drugs (NSAIDs)	0	0.00 – Inf	0.9978
Aspirin as analgesics	0	0.00 – 0.00	0.9996
Steroids	0.59	0.02 – 15.27	0.7478
Selective serotonin reuptake inhibitors (SSRI)	0	NA – Inf	0.9987
Proton pump inhibitors (PPI)	2.21	0.10 – 82.65	0.6110
HMG-CoA inhibitors (statins)	0	0 – 1.858872e+262	0.9988

^*In all variables except of Gender and AgeOp, the references are absence or no use.

^†In the Gender variable, male is the reference.

^††AgeOp – Surgical Age

^†††SubGroup 0 – continue to use antiplatelets, SubGroup 1 – discontinue to use antiplatelets, SubGroup 2 – no use natiplatelets

^††††DAPTG 3, 6, 9, 12, 13 – dual antiplatelet therapy (DAPT) use less than 3 months, 6 months, 9 months, 12 months and over 13 months